Adagio Medical

Executive Summary

Adagio Medical is a private medical device company headquartered in Laguna Hills, California, specializing in innovative cryoablation systems for the treatment of cardiac arrhythmias, particularly atrial fibrillation (AF). The company’s technology is designed to create contiguous, transmural lesions, which are critical for improving procedural efficacy and safety compared to traditional ablation methods. With the global AF market expanding due to an aging population and increasing prevalence of cardiac conditions, Adagio’s focus on precision cryoablation positions it as a potential disruptor in the electrophysiology space. The company has been developing its platform since its founding in 2012 and is backed by a strong intellectual property portfolio. Adagio Medical is currently advancing its lead product through clinical trials, targeting regulatory approval and commercialization. The company’s progress is marked by positive early clinical data and growing interest from strategic partners. In the near term, key milestones include the completion of a pivotal study and submission for FDA clearance. Additionally, Adagio is expected to pursue additional financing to support manufacturing scale-up and commercial launch preparation. The company’s success hinges on demonstrating superior clinical outcomes and safety, which could drive adoption among interventional cardiologists and electrophysiologists. Given the compelling technology and unmet need, Adagio represents a promising but early-stage investment opportunity in the cardiovascular medical device space.

Upcoming Catalysts (preview)

• Q3 2026FDA pre-market approval submission for AFib cryoablation system70% success
• Q2 2026Publication of pivotal trial results in a major cardiology journal75% success
• Q4 2026Series D financing round to fund commercial launch80% success